Dickler, M. N., Saura, C., Richards, D. A., Krop, I. E., Cervantes, A., Bedard, P. L., . . . Baselga, J. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. Clin Cancer Res.
シカゴスタイル引用形Dickler, Maura N., et al. "Phase II Study of Taselisib (GDC-0032) in Combination With Fulvestrant in Patients With HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer." Clin Cancer Res 2018.
MLA引用形式Dickler, Maura N., et al. "Phase II Study of Taselisib (GDC-0032) in Combination With Fulvestrant in Patients With HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer." Clin Cancer Res 2018.
警告: この引用は必ずしも正確ではありません.